CDKN2 (MTS1/p16INK4A) Gene Alterations in Hematological Malignancies

Leukemia and Lymphoma

Volumn 24, Issue 42130, 1997, Pages 449-461

  Uchida, Toshiki ^a   Kinoshita, Tomohiro ^a   Saito, Hidehiko ^a   Hotta, Tomomitsu ^b  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CDKN2 (MTS1 p16INK4A) gene; cell cycle regulator; homozygous deletion; lymphoid malignancy; point mutation

Indexed keywords

CARRIER PROTEIN; PROTEIN P16INK4A; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR;

BLOOD DISEASE; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; POINT MUTATION; REVIEW; TUMOR SUPPRESSOR GENE; ACUTE LYMPHOCYTIC LEUKEMIA; CANCER GENETICS; CARCINOGENESIS; CHROMOSOME 9P; CHRONIC MYELOID LEUKEMIA; GENE MUTATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; T CELL LEUKEMIA;

CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEMATOLOGIC NEOPLASMS; HUMANS; POINT MUTATION;

EID: 0030610476     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428199709055583     Document Type: Article

References (71)

1. Fearon E. R. Oncogenes and tumor suppressor genes. Clinical Oncology, M. D. Abeloff, J. O. Armitage, A. S. Lichter, J. E. Niederhuber. Churchill Livingstone, New York 1995; 11 – 40
2. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., III, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436 – 440
3. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753 – 756
4. Hirama T., Koeffler H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841 – 854
5. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995; 9275: 1149 – 1163
6. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701 – 704
7. Polyak K., Lee M. H., Erdjument-Bromage H., Koff A., Roberts J. M., Tempst P., Massague J. Cloning of p27kp1 a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59
8. Lee M. H., Reynisdottir I., Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Dev. 1995; 9: 639 – 649
9. Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704 – 707
10. Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257 – 261
11. Guan K. L., Jenkins C. W., Li Y., Nichols M. A., Wu X., O'Keefe C. L., Materw A. G., Xiong Y. Growth suppression by p18, a p16INK4A/MST1- and p14INK4 B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes & Dev. 1994; 8: 2939 – 2952
12. Hirai H., Roussel M. F., Kato J., Ashmun R. A., Sherr C. J. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell Biol. 1995; 15: 2672 – 2681
13. Meyerson M., Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell Biol. 1994; 14: 2077 – 2086
14. Hall M., Bates S., Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995; 11: 1581 – 1588
15. Tam S. W., Shay J. W., Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16INK4. Cancer Res. 1994; 54: 5816 – 5820
16. Quelle D. E., Zindy F., Ashmun R. A., Sherr C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993 – 1000
17. Stone S., Jiang P., Dayananth P., Tavtigen S. V., Katcher H., Parry D., Peters G., Kamb A. Complex structure and regulation of p16 (MTS1) locus. Cancer Res. 1995; 55: 2988 – 2994
18. Mao L., Merlo A., Bedi G., Shapiro G. I., Edwards C. D., Rollins B. J., Sidransky D. A novel p16INK4A transcript. Cancer Res. 1995; 55: 2995 – 2997
19. Fueyo J., Gomez-Manzano C., Alfred Tung W. K., Clayman G. L., Liu T. J., Bruner J., Levin V. A., Kyritsis A. P. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies transformed phenotype of glioma cells. Oncogene 1996; 12: 103 – 110
20. Jin X., Nguyen D., Zhang W. W., Kyritsis A. P., Roth J. A. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res. 1995; 55: 3250 – 3253
21. Okamoto A., Hussain S. P., Hagiwara K., Spillare E. A., Rusin M. R., Demetrick D. J., Serrano M., Hannon G. J., Shiseki M., Zariwala M., Xiong Y., Beach D. H., Yokota J., Harris C. C. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 1995; 55: 1448 – 1451
22. Takeuchi S., Bartram C. R., Seriu T., Miller C. W., Tobler A., Janssen J. W. G., Reiter A., Ludwig W. D., Zimmermann M., Schwaller J., Lee E., Miyoshi I., Koeffler H. P. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995; 86: 755 – 760
23. Nakamaki T., Kawamata N., Schwaller J., Tobler A., Fey M., Pakkala S., Lee Y. Y., Kim B. K., Fukuchi K., Tsuruoka N., Kahan J., Miller C. W., Koeffler H. P. Structural integrity of the cyclin-dependent kinase inhibitor genes. p15, p16, p18 in myeloid leukaemias. Br. J. Haematol. 1995; 91: 139 – 149
24. Shiohara M., El-Deiry W. S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D. L., Vogelstein B., Koeffler H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781 – 3784
25. Ponce-Castañeda M. V., Lee M. H., Latres E., Polyak K., Lacombe L., Montgomery K., Mathew S., Krauter K., Sheinfeld J., Massague J., Cordon-Cardo C. p27Kip1: Chromosomal mapping to 12p21-12p13.1 and absence of mutations in human tumors. Cancer Res. 1995; 55: 1211 – 1214
26. Otterson G. A., Kratzke R. A., Coxon A., Kim Y. W., Kaye F. J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994; 9: 3375 – 3378
27. Schmidt E. E., Ichimura K., Reifenberger G., Collins V. P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 1994; 54: 6321 – 6324
28. Lukas J., Aagaard L., Strauss M., Bartek J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res. 1995; 55: 4818 – 4823
29. Hussussian C. J., Struewing J. P., Goldstein A. M., Higgins P. A. T., Ally D. S., Sheahan M. D., Clerk W. H., Tucker M. A., Dracopoli N. C. Germline p16 mutations in familial melanoma. Nature Genet. 1994; 8: 15 – 21
30. Goldstein A. M., Fraser M. C., Struewing J. P., Hussussian C. J., Ranade K., Zametkin D. P., Fontaine L. S., Organic S. M., Dracopoli N. C., Clark W. H., Tucker M. A. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med. 1995; 333: 970 – 974
31. Caldas C., Hahn S. A., Costa L. T., Redston M. S., Schutte M., Seymour A. B., Weinstein C. L., Hruban R. H., Yeo C. J., Kern S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet. 1994; 8: 27 – 32
32. Zuo L., Weger J., Yang Q., Goldstein A. M., Tucker M. A., Walker G. J., Hayward N., Dracopoli N. C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet. 1996; 12: 97 – 99
33. Reed J. A., Loganzo F. J., Shea C. R., Walker G. J., Flores J. F., Glendening J. M., Bogdany J. K., Shiel M. J., Haluska F. G., Fountain J. W., Albino A. P. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2: tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995; 55: 2713 – 2718
34. Nishikawa R., Furnari F. B., Lin H., Arap W., Berger M. S., Cavenee W. K., Su Huang H. J. Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res. 1995; 55: 1941 – 1945
35. Tenan M., Benedetti S., Finocchiaro G. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas. Biochem. Biophys. Res. Commun. 1995; 217: 195 – 202
36. Glendening J. M., Flores J. F., Walker G. J., Stone S., Albino A. P., Fountain J. W. Homozygous loss of the p15INK4B gene (and not the p16INK4A gene) during tumor progression in sporadic melanoma patient. Cancer Res. 1995; 55: 5531 – 5535
37. Heyman M., Rasool O., Brandter L. B., Liu Y., Grandér D., Einhorn S. “Exclusive” p15INK4B gene deletion in acute lymphocytic leukemia include the E1β exon of the p16INK4A gene, (correspondence). Blood 1996; 87, 1657–1658
38. Weinberg R. A. Tumor suppressor gene. Science 1991; 254: 1138
39. Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987; 329: 219 – 222
40. Kundson A. G., Hethcote H. W., Brown B. W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. Natl. Acad. Sci. USA 1975; 72: 5116 – 5120
41. Ogawa S., Hangaishi A., Miyawaki S., Hirosawa S., Miura Y., Takeyama K., Kamada N., Ohtake S., Uike N., Shimazaki C., Toyama K., Hirano M., Mizoguchi H., Kobayashi Y., Furusawa S., Saito M., Emi N., Yazaki Y., Ueda R., Hirai H. Loss of the cyclin-dependent kinase 4-inhibitor (p16;MTS1) gene is frequent in highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995; 86: 1548 – 1556
42. Cairns P., Polascik T. J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., Westra W., Rutter J. L., Buckler A., Gabrielson E., Tockman M., Cho K. R., Hedrick L., Bova G. S., Isaacs W., Koch W., Schwab D., Sidransky D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nature genet. 1995; 11: 210 – 212
43. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1995; 1: 686 – 692
44. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P. J., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common cancers. Cancer Res. 1995; 55: 4525 – 4530
45. Mori T., Miura K., Aoki T., Nishihara T., Mori S., Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I (Multiple Tumor Suppressor/Cylin-dependent Kinase 4 Inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 1994; 54: 3396 – 3397
46. Ranade K., Hussussian C. J., Sikorski R. S., Varmus H. E., Goldstein A. M., Tucker M. A., Serrano M., Hannon G. J., Beach D., Dracopoli N. C. Mutations associated with familial melanoma impair p16INK4 function. Nature genet. 1995; 10: 114 – 116
47. Chilcote R. R., Brown E., Rowley J. D. Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9. N. Engl. J. Med. 1985; 313: 286
48. Okuda T., Shurtleff S. A., Valentine M. B., Raimondi S. C., Head D. R., Behm F., Curcio-Brint A. M., Liu Q., Pui C. H., Sherr C. J., Beach D., Look A. T., Downing J. R. Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995; 85: 2321 – 2330
49. Cayuela J. M., Madani A., Sanhes L., Stern M. H., Sigaux F. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1996; 87: 2180 – 2186
50. Quesnel B., Preudhomme C., Philippe N., Vanrumbeke M., Dervite I., Lai J. L., Bauters F., Wattel E., Fenaux P. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995; 85: 657 – 663
51. Ohnishi H., Kawamura M., Ida K., Sheng X. M., Hanada R., Nobori T., Yamamori S., Hayashi Y. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995; 86: 1269 – 1275
52. Fizzotti M., Cimino G., Pisegna S., Alimena G., Quartarone C., Mandelli F., Pelicci P. G., Lo Coco F. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 1995; 85: 2685 – 2690
53. Uchida T., Watanabe T., Kinoshita T., Murate T., Saito H., Hotta T. Mutational analysis of the CDKN2 (MTS1/p16INK4A) gene in primary B-cell lymphomas. Blood 1995; 86: 2724 – 2731
54. Stranks G., Height S. E., Mitchell P., Jadayel D., Yuille M. A. R., De Lord C., Clutterbuck R. D., Treleaven J. G., Powles R. L., Nacheva E., Oscier D. G., Karpas A., Lenoir G. M., Smith S. D., Millar J. L., Catovsky D., Dyer M. J. S. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 1995; 85: 893 – 901
55. Koduru P. R. K., Zariwala M., Soni M., Gong J. Z., Xiong Y., Broome J. D. Deletion of cyclin-dependent kinase 4 inhibitor genes p15 and p16 in non-Hodgkin's lymphoma. Blood 1995; 86: 2900 – 2905
56. Imamura J., Miyoshi I., Koeffler H. P. p53 in hematologic malignancies. Blood 1994; 84: 2412 – 2421
57. Lo K. W., Huang D. P., Lau K. M. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res. 1995; 55: 2039 – 2043
58. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotrophic virus type 1 infection. Blood 1995; 86: 3619 – 3639
59. Sanada I., Tanaka R., Kumagai E., Tsuda H., Nishimura H., Yamaguchi K., Kawano F., Fujiwara H., Takatsuki K. Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity. Blood 1985; 65: 649 – 654
60. Hatta Y., Hirama T., Miller C. W., Yamada Y., Tomonaga M., Koeffler H. P. Homozygous deletions of p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995; 85: 2699 – 2704
61. Sill H., Goldman J. M., Cross N. C. P. Homozygous deletions of p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995; 85: 2013 – 2016
62. Serra A., Gottardi E., Ragione F. D., Saglio G., Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br. J. Haematol. 1995; 91: 625 – 629
63. Otsuki T., Clark H. M., Wellmann A., Jaffe E. S., Raffeld M. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res. 1995; 55: 1436 – 1440
64. Haider M. A., Cao X. B., Manshouri T., Chan L. L., Glassman A., Kantarjian H. M., Keating M. J., Beran M. S., Albitar M. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood 1995; 86: 311 – 315
65. Newcomb E. W., Rao I. S., Giknavorian S. S., Lee S. Y. Alterations of multiple tumor suppressor genes (p53(17p13), p16INK4A (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia. Mol. Carcinogen. 1995; 14: 141 – 146
66. Carins P., Mao L., Merlo A., Lee D. J., Schwab D., Eby Y., Tokino K., van der Riet P., Blaugrund J. E., Sidransky D., Kamb A., Liu Q., Harshman K., Tavtigian S., Cordon-Cardo C., Skolnick M. H. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265: 415 – 417
67. Hahn S. A., Schutte M., Hoque A. T. M. S., Moskaluk C. A., da Costa L. T., Rozenblum E., Weinstein C. L., Fischer A., Yeo C. J., Hruban R. H., Kern S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350 – 353
68. Puig S., Ruiz A., Lazaro C., Castel T., Lynch M., Palou J., Vilalta A., Weissenbach J., Mascaro M. J., Estivill X. Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. Am. J. Hum. Genet., 57: 395 – 402
69. Spruck C. H., III, Gonzales-Zulueta M., Shibata A., Simoneau A. R., Lin M. F., Gonzales F., Tsai Y. C., Jones P. A. p16 gene in uncultured tumors. Nature 1994; 370: 183 – 184
70. Kyritsis A. P., Zhang B., Zhang W., Xiao M., Takeshima H., Bondy M. L., Cunningham J. E., Levin V. A., Bruner J. Mutations of p16 gene in gliomas. Oncogene 1996; 12: 63 – 67
71. Kratzke R. A., Otterson G. A., Lincoln C. E., Ewing S., Oie H., Geradts J., Kaye F. J. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J. Natl. Cancer Inst. 1995; 87: 1870 – 1875